Amphotericin B (Liposomal)Third Party Manufacturing in India

Liposomal amphotericin B is a broad-spectrum polyene antifungal agent that works by binding to ergosterol, the principal sterol component of fungal cell membranes. The drug is encapsulated within unilamellar liposomes composed of hydrogenated soy phosphatidylcholine, distearoylphosphatidylglycerol, and cholesterol. This liposomal formulation is designed to carry amphotericin B safely through the bloodstream while minimizing interaction with mammalian cell membranes. When the liposome encounters a fungal cell, it binds to the cell wall and transits intact through the cell wall matrix — a process made possible by the viscoelastic and deformable properties of the fungal cell wall. Once the liposome reaches the fungal cell membrane, amphotericin B is released because it has a ten-fold higher binding affinity for ergosterol compared to cholesterol in the liposome. The released amphotericin B molecules insert into the fungal cell membrane and assemble into transmembrane pores or ion channels. These pores disrupt the membrane's selective permeability, causing leakage of essential intracellular ions such as potassium, magnesium, and calcium, along with other small molecules. The resulting ionic imbalance and metabolic disruption lead to rapid fungal cell death. Additionally, amphotericin B induces oxidative damage within the fungal cell through generation of reactive oxygen species. The liposomal formulation significantly reduces the nephrotoxicity and infusion-related reactions associated with conventional amphotericin B deoxycholate.

Liposomal amphotericin B is a broad-spectrum antifungal agent used for the treatment of serious, life-threatening systemic fungal infections. It is available as a lyophilized powder for reconstitution and intravenous infusion in 50 mg/vial strength.

Therapeutic Uses

• Invasive Candidiasis: Treatment of systemic Candida infections including candidemia, intra-abdominal abscesses, peritonitis, and hepatosplenic candidiasis in immunocompromised patients
• Invasive Aspergillosis: First-line therapy for pulmonary and disseminated aspergillosis, particularly in neutropenic patients and hematopoietic stem cell transplant recipients
• Cryptococcal Meningitis: Induction therapy for HIV-associated cryptococcal meningitis and other cryptococcal infections of the central nervous system
• Visceral Leishmaniasis: Effective treatment option for leishmaniasis, especially in immunocompromised patients and in regions with antimonial resistance
• Empirical Antifungal Therapy: Recommended for febrile neutropenic patients with suspected fungal infections not responding to broad-spectrum antibiotics
• Mucormycosis: Treatment of life-threatening mucormycosis infections including rhinocerebral, pulmonary, and disseminated forms

Why Manufacturers Choose Liposomal Amphotericin B

Liposomal amphotericin B is a high-value, complex injectable antifungal with strong demand in hospital and institutional settings worldwide. The liposomal formulation requires specialized manufacturing capabilities including high-pressure homogenization, sterile filtration, and aseptic lyophilization — making it a technologically advanced product with significant entry barriers. Indian manufacturers with advanced lipid-based drug delivery expertise and WHO-GMP certified facilities are well-positioned to serve both domestic tender demand and regulated export markets requiring complex injectable capabilities.

This makes Liposomal Amphotericin B one of the most sought-after molecules for third party manufacturing in India, with consistent demand from institutional buyers and export-oriented pharmaceutical companies.